Cognigy Secures Funding to Meet Growing Demand for Conversational AI in Asia-Pacific
28.1.2021 09:00:00 EET | Business Wire | Press release
Cognigy today announced a secured investment funding from Global Brain, one of Japan’s largest venture capital firms. The funding will enable Cognigy to capitalize on its position as a leader in Conversational AI and customer service automation in high-growth markets such as the Asia-Pacific region.
“Cognigy’s team has impressed us with its bold vision, superb technology, and strong traction. Their low-code conversational AI platform allows companies across industries to easily automate customer engagement processes and is raising the bar on corporate customer experiences. We are excited to join Cognigy’s journey and look forward to supporting its expansion in Asian markets,” said Rina Obi, Principal at Global Brain.
Elevating CX Performance With AI
As customer expectations continue to evolve, Cognigy’s top priority is to equip contact centers with AI-first technology to resolve customer issues at unmatched speed and consistency. Its robust Conversational AI platform easily integrates into existing tools to successfully scale support and permeate more channels for customers.
“Conversational AI is a major driving force in today’s digital transformation of Customer Service in every industry on every continent,” said Philipp Heltewig, CEO and co-founder of Cognigy. “This funding will accelerate Cognigy’s globalization strategy to help businesses improve their customer experiences while driving greater operational efficiency, strengthening our position as the leader in customer service automation.”
The Pinnacle of Intelligence
Built on the premise that Conversational AI could rival the power of customer service agents with the same human-like quality at lower costs, Cognigy aims to catalyze this unique convergence of conversation and processes. From next-gen Conversational IVR to ICR and virtual support agents to automated voice calls, Cognigy has a proven track record for innovation and responsiveness in delivering business outcomes.
At the heart of Cognigy’s solution is Cognigy.AI, a low-code platform that abstracts away the underlying complexity of artificial intelligence, making building and deploying cognitive bot interfaces a familiar experience to not just developers but also business users, conversation designers, project managers, and more.
About Cognigy
Cognigy is a global leader in Conversational AI to support customer service automation. Its low-code platform, Cognigy.AI, enables enterprises to automate contact centers for customer and employee communications using intelligent voice- and chatbots. With precise, reliable intent recognition, human-like dialogs and seamless integration into backend systems, Cognigy.AI creates superior user experiences and helps companies reduce support costs. Cognigy.AI is available in SaaS and on-premise environments and supports conversations in any language and on any channel including phone, webchat, SMS and mobile apps. Cognigy’s worldwide client portfolio includes Daimler, Bosch, Henkel, Lufthansa, Salzburg AG and many more. Learn more at cognigy.com.
About Global Brain
Global Brain is an early-stage venture capital firm based in Tokyo. It supports startups that tackle pressing problems, create innovation, and contribute to the stimulation of the Japanese economy and beyond. Its high-achieving, experienced professionals identify excellent startups through multiple global locations in Europe, US and APAC, and provide hands-on growth support. Global Brain’s total asset under management is over US$1 billion, making it the largest domestic independent venture capital firm. To learn more visit globalbrains.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210127005099/en/
Contact information
Muriel Klusmann
SVP Marketing, Cognigy
Düsseldorf, Germany
marketing@cognigy.com
+49 211 54591991
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Safe Software to Increase Global Headcount by Over 15% as Demand for AI-Ready Data Grows2.9.2026 16:00:00 EEST | Press release
Safe Software, the creator of FME, the only All-Data, Any-AI enterprise integration platform with true support for spatial data, today announced it is recruiting for more than 60 roles throughout the remainder of 2026. The hiring will take the company past 400 employees, increasing headcount by over 15%, with new positions across the United Kingdom, the United States and Canada. The expansion follows a year in which Safe crossed $100 million in annual revenue, growing close to 20 percent year over year and moving ahead of schedule on its target of $250 million by 2028. The company also grew its employee base by over 20% in the same period. "The incredible growth that we’ve seen over the last 30+ years at Safe has always been a testament to the great people behind what we do," said Don Murray, Co-Founder and CEO of Safe Software. "Almost every organization we speak to is trying to get its data ready for AI, and most of them are realizing that the hard part is not the model, it is the da
Egon Zehnder Names Ayşe Güçlü Onur Global Human Resources Practice Leader2.9.2026 16:00:00 EEST | Press release
Egon Zehnder has appointed Ayşe Güçlü Onur as Global Leader of its Human Resources Practice. This appointment comes as companies and boards increasingly look to CHROs to help shape business strategy, lead transformation, build leadership pipelines, and navigate major shifts in culture and the workforce. "CHROs used to be evaluated by how well they supported the business. Today, the best drive it," said Onur. "Our role is to help CHROs move from a seat at the table to a hand in business growth. We help them connect leadership decisions, talent, and culture directly to elevated performance. That's the shift Egon Zehnder is built to guide with our leadership advisory services." Egon Zehnder’s Human Resources Practice partners with companies to discover, develop, and transform future-ready CHROs, helping them shape the future of the function. This includes executive search, leadership assessment and development, board effectiveness, culture, succession planning, organizational transformati
Owkin to License K Pro AI Scientist and Multimodal Oncology and Immunology Data to Boehringer Ingelheim2.9.2026 15:00:00 EEST | Press release
Owkin, the agentic AI company striving to transform drug discovery and development for biopharma, today announced a license agreement with Boehringer Ingelheim for K Pro, Owkin’s AI Scientist, together with multimodal patient data, aiming to speed up the discovery process across multiple indications in oncology and immunology. This agreement builds upon an initial pilot undertaken by Owkin with Boehringer in 2025. In that pilot Owkin delivered deep spatial insights into the tumor microenvironment of a gene target through its MOSAIC dataset. Under the new agreement, Owkin will license multimodal oncology data to Boehringer and will generate new multimodal data in immunology. Owkin licenses, sources and generates multimodal patient data in collaboration with its global patient data network. Boehringer Ingelheim’s teams will access and analyze this data through K Pro, which provides a single environment to interrogate data and run reproducible analyses. K Pro’s reasoning capabilities supp
Biocytogen Enters into Non-Exclusive Licensing Agreement with Qilu Pharmaceutical for a Fully Human VHH Antibody to Support Innovative Drug Development in Neuroscience2.9.2026 15:00:00 EEST | Press release
Biocytogen Pharmaceuticals (Beijing) Co., Ltd. (“Biocytogen”, SSE: 688796; HKEX: 02315) today announced that it has entered into a non-exclusive licensing agreement with Qilu Pharmaceutical Co., Ltd. (“Qilu Pharmaceutical”) for a fully human VHH antibody molecule. Under the agreement, Biocytogen will grant Qilu Pharmaceutical non-exclusive rights to a fully human VHH antibody molecule to support its research and development of innovative therapeutics in the neuroscience field. The licensed VHH antibody molecule was generated from Biocytogen’s proprietary RenNano® platform. The RenNano® platform is designed to discover fully human VHH antibody molecules with favorable specificity, binding affinity, and developability, and can generate molecular building blocks for the design and development of VHH antibodies, bispecific/multispecific antibodies, antibody-drug conjugates, and other innovative modalities. Through this license, Qilu Pharmaceutical may advance the research and development o
Croma-Pharma Introduces Electronic Instructions for Use Across the saypha ® Portfolio2.9.2026 14:37:00 EEST | Press release
Croma-Pharma has introduced electronic Instructions for Use (eIFU) across its saypha® portfolio in markets where applicable regulations permit electronic Instructions for Use to replace printed versions. The transition expands digital access to essential product information for healthcare professionals while reducing the use of printed documentation. Healthcare professionals can access the current approved Instructions for Use by scanning the QR code on the saypha® folding box. The eIFU platform provides direct digital access to the latest approved Instructions for Use. "Innovation extends beyond product development. It also includes how we provide healthcare professionals with access to essential product information," said Andreas Prinz, Chief Executive Officer of Croma-Pharma. "The introduction of electronic Instructions for Use across the saypha® portfolio reflects our focus on practical digital solutions that support healthcare professionals and align with evolving regulatory requi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom